Mariateresa Fulciniti

Mariateresa Fulciniti

Auto-generated profile, based on publicly available information

Mariateresa Fulciniti

Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
MSMehmet Kemal Samur
Mehmet Kemal Samur
MFMariateresa Fulciniti
Mariateresa Fulciniti
ASAnil Aktas Samur
Anil Aktas Samur
ABAbdul Hamid Bazarbachi
Abdul Hamid Bazarbachi
YTYu-Tzu Tai
Yu-Tzu Tai
NMNikhil C. Munshi
Nikhil C. Munshi
BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined. Here, we perform single cell genomic characterization of longitudinal samples from a patient who relapsed after initial CAR T cell treatment with lack of response to retreatment. We report selection, following initial CAR T cell infusion, of a clone with biallelic loss of BCMA acquired by deletion of one allele and a mutation that creates an early stop codon on the second allele. This loss leads to lack of CAR T cell proliferation following the second infusion and is reflected by lack of soluble BCMA in patient serum. Our analysis suggests the need for careful detection of BCMA gene alterations in multiple myeloma cells from relapse following CAR T cell therapy.

27 December 2018 in Blood
Verified
Journal Article
Open access
PDF file
ACAlice Cleynen
Alice Cleynen
MSMehmet Kemal Samur
Mehmet Kemal Samur
Aurore PerrotAurore Perrot
Aurore Perrot
LBLaure Buisson
Laure Buisson
SMSabrina Maheo
Sabrina Maheo
Jill CorreJill Corre
Jill Corre

16 May 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MBMoritz Binder
Moritz Binder
RSRaphael E. Szalat
Raphael E. Szalat
STSrikanth Talluri
Srikanth Talluri
MFMariateresa Fulciniti
Mariateresa Fulciniti
HAHervé Avet-Loiseau
Hervé Avet-Loiseau
NMNikhil C. Munshi
Nikhil C. Munshi
The natural history of multiple myeloma is characterized by its localization to the bone marrow and its interaction with bone marrow stromal cells. The bone marrow stromal cells provide growth and survival signals, thereby promoting the development of drug resistance. Here, we show that the interaction between bone marrow stromal cells and myeloma cells (using human cell lines) induces chromatin remodeling of cis-regulatory elements and is associated with changes in the expression of genes involved in the cell migration and cytokine signaling. The expression of genes involved in these stromal interactions are observed in extramedullary disease in patients with myeloma and provides the rationale for survival of myeloma cells outside of the bone marrow microenvironment. Expression of these stromal interaction genes is also observed in a subset of patients with newly diagnosed myeloma and are akin to the transcriptional program of extramedullary disease. The presence of such adverse stromal interactions in newly diagnosed myeloma is associated with accelerated disease dissemination, predicts the early development of therapeutic resistance, and is of independent prognostic significance. These stromal cell induced transcriptomic and epigenomic changes both predict long-term outcomes and identify therapeutic targets in the tumor microenvironment for the development of novel therapeutic approaches.

20 December 2022 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
ASAnil Aktas Samur
Anil Aktas Samur
MFMariateresa Fulciniti
Mariateresa Fulciniti
HAHerve Avet-Loiseau
Herve Avet-Loiseau
MLMichael A. Lopez
Michael A. Lopez
SDSanika Derebail
Sanika Derebail
NMNikhil C. Munshi
Nikhil C. Munshi
Splicing changes are common in cancer and are associated with dysregulated splicing factors. Here, we analyzed RNA-seq data from 323 newly diagnosed multiple myeloma (MM) patients and described the alternative splicing (AS) landscape. We observed a large number of splicing pattern changes in MM cells compared to normal plasma cells (NPC). The most common events were alterations of mutually exclusive exons and exon skipping. Most of these events were observed in the absence of overall changes in gene expression and often impacted the coding potential of the alternatively spliced genes. To understand the molecular mechanisms driving frequent aberrant AS, we investigated 115 splicing factors (SFs) and associated them with the AS events in MM. We observed that ~40% of SFs were dysregulated in MM cells compared to NPC and found a significant enrichment of SRSF1, SRSF9, and PCB1 binding motifs around AS events. Importantly, SRSF1 overexpression was linked with shorter survival in two independent MM datasets and was correlated with the number of AS events, impacting tumor cell proliferation. Together with the observation that MM cells are vulnerable to splicing inhibition, our results may lay the foundation for developing new therapeutic strategies for MM. We have developed a web portal that allows custom alternative splicing event queries by using gene symbols and visualizes AS events in MM and subgroups. Our portals can be accessed at http://rconnect.dfci.harvard.edu/mmsplicing/ and https://rconnect.dfci.harvard.edu/mmleafcutter/.

11 December 2023 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
DDDebasmita Dutta
Debasmita Dutta
Jiye LiuJiye Liu
Jiye Liu
KWKenneth Wen
Kenneth Wen
KKKeiji Kurata
Keiji Kurata
MFMariateresa Fulciniti
Mariateresa Fulciniti
KAKenneth Anderson
Kenneth Anderson
Bortezomib (BTZ) is a standard-of-care treatment in multiple myeloma (MM); however, adverse side effects and development of resistance limit its long term benefit. To improve target specificity, therapeutic efficacy, and overcome resistance, we designed nanoparticles that encapsulate BTZ and are surface-functionalized with BCMA antibodies (BCMA-BTZ-NPs). We confirmed efficient cellular internalization of the BCMA-BTZ-NPs only in BCMA-expressing MM cells, but not in BCMA-knockout (KO) cells. In addition, BCMA-BTZ-NPs showed target-specific cytotoxicity against MM cell lines and primary tumor cells from MM patients. The BCMA-BTZ-NPs entered the cell through receptor-mediated uptake, which escapes a mechanism of BTZ resistance based on upregulating P-glycoprotein. Furthermore, BCMA-BTZ-NPs induced cell death more efficiently than non-targeted nanoparticles or free BTZ, triggering potent mitochondrial depolarization followed by apoptosis. In BTZ-resistant cells, BCMA-BTZ-NPs inhibited proteasome activity more effectively than free BTZ or non-targeted nanoparticles. Additionally, BCMA-BTZ-NPs enhanced immunogenic cell death and activated the autophagic pathway more than free BTZ. Finally, we found that BCMA-BTZ-NPs selectively accumulated at the tumor site in a murine xenograft model, enhanced tumor reduction, and prolonged host survival. These results suggest BCMA-BTZ-NPs provide a promising therapeutic strategy for enhancing the efficacy of BTZ and establish a framework for their evaluation in a clinical setting.

21 June 2021 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
SSShayna Sarosiek
Shayna Sarosiek
CVCindy Varga
Cindy Varga
AJAllison Jacob
Allison Jacob
MFMaria Teresa Fulciniti
Maria Teresa Fulciniti
NMNikhil Munshi
Nikhil Munshi
VSVaishali Sanchorawala
Vaishali Sanchorawala